Skip to search formSkip to main contentSkip to account menu

Sulfinpyrazone

Known as: Sulphinpyrazone, 3,5-Pyrazolidinedione, 1,2-diphenyl-4-(2-(phenylsulfinyl)ethyl)-, Sulfoxyphenylpyrazolidine 
A phenylbutazone derivative with uricosuric and antithrombotic properties. Sulfinpyrazone competitively inhibits reabsorption of urate at the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Relatively few selective substrate and inhibitor probes have been identified for human UDP-glucuronosyltransferases (UGTs). This… 
Review
1998
Review
1998
Accumulating evidence indicates that CYP2C9 ranks amongst the most important drug metabolizing enzymes in humans. Substrates for… 
Review
1994
Review
1994
Warfarin is the most widely used oral anticoagulant drug in North America, in part because of its relatively predictable onset… 
Review
1988
Review
1988
Thirty one randomised trials of antiplatelet treatment for patients with a history of transient ischaemic attack, occlusive… 
Highly Cited
1985
Highly Cited
1985
We performed a randomized, double-blind, placebo-controlled trial in 555 patients with unstable angina who were hospitalized in… 
Highly Cited
1983
Highly Cited
1983
The effect of sulfinpyrazone on endothelial injury induced by homocysteine has been studied both in vitro, using cultured human… 
Highly Cited
1978
Highly Cited
1978
  • The New England journal of medicine
  • 1978
  • Corpus ID: 10267616
Five hundred and eighty-five patients with threatened stroke were followed in a randomized clinical trial for an average of 26…